Aviado · Research
Longevity Daily
Friday, June 19, 2026
Listen
Today's Brief
Today's must-read is a Lancet RCT of 365 older adults that found high-dose DHA reached the brain but produced zero cognitive benefit over two years — one of the most important omega-3 findings in years. New eye-scan data links retinal vessel changes to sharply elevated Alzheimer's risk, and a Nature study identifies conserved blood proteins that score biological aging in real time. Also this issue: green spaces cut Alzheimer's risk by 14%, UCL prepares the first human immune rejuvenation trial, and Aviado Research examines the evidence base for today's leading longevity interventions.
10 stories7 peer-reviewed2 trials1 Aviado original
Cognitive Health & Neuroprotection
A Routine Eye Scan Can Predict Alzheimer's Risk -- Here's What to Ask Your Doctor
Optical coherence tomography angiography (OCT-A) -- a non-invasive eye scan already available in many ophthalmology clinics -- is emerging as a powerful early biomarker for cognitive decline. New data shows that each 1-percentage-point drop in vessel surface density raises MCI risk by 21% and dementia risk by 34%, while changes in capillary flow density compound those odds further. It's not yet a standard screening tool, but if you're proactive about brain health, this is worth raising at your next eye exam.
Read more →Green Space Exposure Linked to 14% Lower Alzheimer's Risk in Large Population Study
Analyzing a large population dataset, researchers found that greater access to green spaces -- parks, trees, and urban nature -- was associated with a significant 14% reduction in Alzheimer's disease risk (HR 0.86, 95% CI 0.79-0.95). The protective signal extended across multiple neurodegenerative conditions, not just Alzheimer's. This is observational data and cannot confirm causation, but it adds meaningfully to the case that nature exposure is a legitimate component of a brain-protective lifestyle.
Read more →Supplements & Compounds
High-Dose DHA Reaches the Brain but Delivers Zero Cognitive Benefit Over 24 Months
A rigorous randomized, double-blind, placebo-controlled trial -- the gold standard of science -- published in *eBioMedicine* enrolled 365 adults aged 55-80 without dementia and confirmed that high-dose DHA successfully elevated omega-3 concentrations in the brain, achieving biochemical CNS target engagement. Despite that, participants showed no improvements in cognition, memory, or brain structure over two full years. The null result held regardless of APOE ε4 status, eliminating the gene variant often invoked to explain why certain people might need more DHA. If you're taking omega-3s specifically for brain protection, this is the most methodologically rigorous evidence yet that high-dose DHA supplementation alone is not the lever -- and researchers now recommend focusing on brain DHA metabolism rather than supplementing more.
Read more →Antioxidants Can Selectively Clear Senescent Cells in Muscle -- If the Mechanism Is Right
A study in *Aging Cell* describes how certain antioxidants selectively eliminate senescent cells in muscle tissue by disrupting mTOR signaling -- the pathway these so-called zombie cells exploit to evade immune clearance. The effect is cell-type specific, meaning blanket antioxidant supplementation won't replicate it across all tissues. This adds important nuance to both the antioxidant debate and the emerging senolytics field, suggesting that targeted antioxidant use may be more therapeutically meaningful than previously appreciated.
Read more →Research & Papers
Three Blood Proteins Track Your Aging Speed -- and They Work the Same Way in Mice and Humans
A landmark *Nature* study provides the most comprehensive evidence yet that aging follows a conserved molecular script across species, identifying a set of blood proteins that reflect biological age in both mice and humans. Researchers built a scoring system from these proteins that can be calculated directly from a blood sample in real time. While this is foundational science rather than a clinical tool, it moves universal aging biomarkers significantly closer to practical reality -- and may eventually help evaluate whether a given longevity intervention is actually working.
Read more →Biological Age Clocks Are More Predictive Than Ever -- But Not Ready for Individual Decisions
A major review in the *Journal of Clinical Investigation* maps the current landscape of biological age measurement -- from grip strength and routine blood markers to epigenetic clocks, proteomics, wearables, and AI-driven models -- finding that these tools meaningfully outperform chronological age for predicting health risk at the population level. However, the review is candid about significant limitations that prevent reliable application to individual clinical decisions. If you're tracking your biological age with a consumer test, this is an important reality check on what those numbers actually mean.
Read more →Aviado Research: A Critical Look at the Evidence for Today's Longevity Interventions
Aviado Research's latest analysis examines the strength of evidence behind leading longevity interventions, providing an expert framework for distinguishing well-supported approaches from those still lacking rigorous human data. Essential reading for anyone trying to navigate an increasingly crowded field of supplements and therapeutics.
Read the full Aviado analysis →Lifestyle & Nutrition
Diet, Weight Loss, and 150 Minutes of Weekly Exercise Beat Metformin for Chronic Disease Prevention
A long-term analysis of the Diabetes Prevention Program Outcomes Study (DPPOS), tracking 1,173 participants with prediabetes, found that three combined lifestyle changes -- dietary improvement, modest weight loss, and at least 150 minutes of weekly exercise -- reduced risk across multiple chronic diseases by 21%, outperforming metformin on that broad measure. For anyone managing metabolic risk or prediabetes, the evidence continues to point firmly toward structured lifestyle intervention as the superior first-line defense.
Read more →Industry & Policy
UCL Launches First-Ever Human Trial to Reverse Immune Aging in T Cells
University College London is preparing to launch a first-in-human clinical trial of an immune rejuvenation therapy designed to restore function in exhausted T cells -- the immune cells most depleted by aging. Built on decades of UCL aging immunology research, the therapy targets immune exhaustion directly, aiming to restore older adults' immune competence. If it succeeds, this would represent one of the first direct interventions against immune aging in humans -- a critical frontier given that immune dysfunction underlies virtually every major age-related disease.
Read more →